PharmExec6d
FDA Approves GSK’s Blujepa for Uncomplicated Urinary Tract Infections
Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 ...
Can GSK's Blujepa provide relief from UTIs amid rising bacterial resistance and declining treatment efficacy?
The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the ...
PMLive6d
GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections
GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat ...
MyChesCo on MSN2d
FDA Approves GSK’s Blujepa as First New Oral Antibiotic for UTIs in 30 Years
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
Here’s what to know about Blujepa, the new FDA-approved UTI treatment heading to market this year
GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...
Verywell Health on MSN1d
A New FDA-Approved Antibiotic May Help Women With Recurring UTIs
If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
MedCity News6d
FDA Approves First-in-Class GSK Antibiotic for Common Type of Urinary Tract Infection
The drug, known in development as gepotidacin, will be marketed under the brand name Blujepa. GSK said it plans to launch the new product in the second half of this year. Uncomplicated UTIs are ...
Endocrinology Advisor14h
FDA Approves Blujepa for Uncomplicated UTI in Female Patients
The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.
GSK’s share price looks a steal to me anywhere below £43.29, and here’s why
GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I'd seen in the stock before that. The post GSK’s share price looks a steal to me ...
Pharmabiz5d
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...
pharmaphorum3d
GSK ends decades-long hiatus in oral antibiotics for UTIs
"The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women," said GSK's chief scientific offer Tony Wood, pointing out that around 16 million women in the ...